Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (68Ga-BBN-RGD).

Iagaru AH.

J Nucl Med. 2017 Mar 9. pii: jnumed.117.191478. doi: 10.2967/jnumed.117.191478. [Epub ahead of print] No abstract available.

PMID:
28280224
2.

Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.

Sonni I, Baratto L, Iagaru A.

PET Clin. 2017 Apr;12(2):159-171. doi: 10.1016/j.cpet.2016.11.003. Review.

PMID:
28267450
3.

Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method.

Lapa P, Marques M, Costa G, Iagaru A, Pedroso de Lima J.

Nucl Med Commun. 2017 Apr;38(4):325-332. doi: 10.1097/MNM.0000000000000654.

PMID:
28230714
4.

Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience.

Ter Voert EE, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, Iagaru AH, Zaharchuk G, Huellner M, Delso G.

Eur J Nucl Med Mol Imaging. 2017 Jan 26. doi: 10.1007/s00259-017-3619-2. [Epub ahead of print]

PMID:
28124091
5.

Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI.

Minamimoto R, Iagaru A, Jamali M, Holley D, Barkhodari A, Vasanawala S, Zaharchuk G.

PLoS One. 2017 Jan 19;12(1):e0167262. doi: 10.1371/journal.pone.0167262.

6.

Bombesin-Targeted PET of Prostate Cancer.

Mansi R, Minamimoto R, Mäcke H, Iagaru AH.

J Nucl Med. 2016 Oct;57(Suppl 3):67S-72S.

PMID:
27694175
7.

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

Iagaru AH, Mittra E, Colletti PM, Jadvar H.

J Nucl Med. 2016 Oct;57(Suppl 3):19S-24S.

PMID:
27694165
8.

Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.

Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS.

Radiology. 2016 Jul;280(1):328. doi: 10.1148/radiol.2016164020. No abstract available.

PMID:
27322985
9.

PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies.

Sonni I, Iagaru A.

PET Clin. 2016 Jul;11(3):261-72. doi: 10.1016/j.cpet.2016.02.007. Review.

PMID:
27321030
10.

Editorial Comment.

Iagaru A.

J Urol. 2016 Aug;196(2):390. doi: 10.1016/j.juro.2016.02.2998. No abstract available.

PMID:
27207378
11.

Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation.

Guo HH, Moradi F, Iagaru A.

Nucl Med Commun. 2016 Sep;37(9):975-82. doi: 10.1097/MNM.0000000000000531.

PMID:
27111100
12.

The potential of TOF PET-MRI for reducing artifacts in PET images.

Iagaru A, Minamimoto R, Levin C, Barkhodari A, Jamali M, Holley D, Greg Z.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A77. doi: 10.1186/2197-7364-2-S1-A77. No abstract available.

13.

Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI.

Iagaru A, Minamimoto R, Jamali M, Barkodhodari A, Gambhir SS, Vasanawala S.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A65. doi: 10.1186/2197-7364-2-S1-A65. No abstract available.

14.

Whole-body simultaneous time-of-flight PET-MRI: early experience with clinical studies.

Minamimoto R, Iagaru A, Jamali M, Barkodhodari A, Holley D, Vasanawala S, Zaharchuk G.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A64. doi: 10.1186/2197-7364-2-S1-A64. No abstract available.

15.

Dynamic brain PET/MR using TOF reconstruction.

Khalighi MM, Delso G, Tohme M, Iagaru A, Zaharchuk G.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A60. doi: 10.1186/2197-7364-2-S1-A60. No abstract available.

16.

A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners.

Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, Iagaru A.

Clin Nucl Med. 2016 Jul;41(7):e323-6. doi: 10.1097/RLU.0000000000001170.

PMID:
26914563
17.

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.

Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS.

PLoS One. 2016 Feb 18;11(2):e0148628. doi: 10.1371/journal.pone.0148628.

18.

Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI.

Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, Iagaru A.

Mol Imaging Biol. 2016 Oct;18(5):776-81. doi: 10.1007/s11307-016-0939-8.

PMID:
26884058
19.

Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors.

Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mittra ES, Iagaru A.

Clin Nucl Med. 2016 Jun;41(6):e281-7. doi: 10.1097/RLU.0000000000001100.

PMID:
26673240
20.

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.

Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.

J Nucl Med. 2016 Apr;57(4):557-62. doi: 10.2967/jnumed.115.168393.

PMID:
26659347

Supplemental Content

Loading ...
Support Center